GL0034

Phase 2Small molecule

Sun Pharmaceutical Industries Limited

GL0034 is one of 77 small molecule programs targeting Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetes MellitusActive, not recruiting

Renal InsufficiencyActive, not recruiting

Diabetes MellitusPhase 2

Active, not recruiting

Renal InsufficiencyPhase 1

Active, not recruiting

Competition

Competitive Landscape

286 competitors in Diabetes Mellitus

#DrugCompanyPhaseTrials

Lispro

Eli Lilly

Phase 3

1 2

Byetta

AstraZeneca

Preclinical

2 3

Trulicity

Eli Lilly

Preclinical

2 4

Galvus

Novartis

Preclinical

1 5

Simponi

Johnson & Johnson

Preclinical

1 6

Paxil CR

GSK

Preclinical

1 7

Edarbi

Takeda

Preclinical

1 8

NOVOLIN R

Novo Nordisk

Preclinical

1 9

Insulin 320

Novo Nordisk

Preclinical

10 10

Cymbalta

Alnylam Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Renal Insufficiency

NCT07385547

Q3 2027

Phase 2Recruiting

Diabetes Mellitus

NCT07282743

Clinical

Trials by Indication[1]

Diabetes Mellitus1 trial

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

Recruiting· Sun Pharmaceutical Industries Limited logo

Sun Pharmaceutical Industries Limited·Phase 2·NCT07282743·285 enrolled

Renal insufficiency1 trial

Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency

Recruiting· Sun Pharmaceutical Industries Limited logo

Sun Pharmaceutical Industries Limited·Phase 1·NCT07385547·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GL0034. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GL0034 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GL0034. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Pharmaceutical Industries Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sun Pharmaceutical Industries Limited

GL0034

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Trials by Indication[1]

Diabetes Mellitus1 trial

Renal insufficiency1 trial

References

Drug Info

Quick Facts

Related News